{"id":2732,"date":"2020-06-25T00:00:00","date_gmt":"2021-03-18T02:29:30","guid":{"rendered":"https:\/\/www.eisai.com.cn\/?p=2732"},"modified":"2022-03-11T14:02:01","modified_gmt":"2022-03-11T06:02:01","slug":"%e5%8d%ab%e6%9d%90%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%b8%95%e9%87%91%e6%a3%ae%e7%97%85%e7%9a%84equfina%e7%89%87%e5%89%82%e5%9c%a8%e9%9f%a9%e5%9b%bd%e8%8e%b7%e5%be%97%e6%89%b9%e5%87%86","status":"publish","type":"post","link":"https:\/\/www.eisai.com.cn\/2020\/06\/25\/%e5%8d%ab%e6%9d%90%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%b8%95%e9%87%91%e6%a3%ae%e7%97%85%e7%9a%84equfina%e7%89%87%e5%89%82%e5%9c%a8%e9%9f%a9%e5%9b%bd%e8%8e%b7%e5%be%97%e6%89%b9%e5%87%86\/","title":{"rendered":"\u536b\u6750\u7528\u4e8e\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u7684EQUFINA\u00ae\u7247\u5242\u5728\u97e9\u56fd\u83b7\u5f97\u6279\u51c6"},"content":{"rendered":"
\u536b\u6750\u682a\u5f0f\u4f1a\u793e\uff08\u603b\u90e8\uff1a\u4e1c\u4eac\uff0c\u9996\u5e2d\u6267\u884c\u5b98\uff1a\u5185\u85e4\u6674\u592b\uff0c\u4ee5\u4e0b\u7b80\u79f0\u201c\u536b\u6750\u201d\uff09\u8fd1\u65e5\u5ba3\u5e03\uff0c\u536b\u6750\u5728\u97e9\u5b50\u516c\u53f8\u536b\u6750\u682a\u5f0f\uff08\u97e9\u56fd\uff09\u4f1a\u793e\u5df2\u83b7\u5f97\u97e9\u56fd\u76d1\u7ba1\u673a\u6784\uff08\u98df\u54c1\u548c\u836f\u54c1\u5b89\u5168\u90e8\uff09\u6240\u6388\u4e88\u7684\u5173\u4e8e\u5e15\u91d1\u68ee\u75c5\u6cbb\u7597\u836f\u7269Equfina\u00ae\uff08\u7532\u78fa\u9178\u6c99\u82ac\u9170\u80fa\uff0c\u4ee5\u4e0b\u7b80\u79f0\u201c\u6c99\u82ac\u9170\u80fa\u201d\uff09\u7684\u4e0a\u5e02\u8bb8\u53ef\uff0c\u8be5\u836f\u4f5c\u4e3a\u542b\u5de6\u65cb\u591a\u5df4\u836f\u7269\u7684\u52a0\u7528\u6cbb\u7597\uff0c\u7528\u4e8e\u6cbb\u7597\u4f34\u5242\u672b\u8fd0\u52a8\u6ce2\u52a8\u7684\u539f\u53d1\u6027\u5e15\u91d1\u68ee\u75c5\u60a3\u8005\u30022019\u5e747\u6708\u5df2\u4e8e\u97e9\u56fd\u63d0\u4ea4\u6c99\u82ac\u9170\u80fa\u7684\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\uff0c\u901a\u8fc7\u6279\u51c6\u8be5\u7533\u8bf7\uff0c\u97e9\u56fd\u6210\u4e3a\u9664\u65e5\u672c\u4e4b\u5916\u4e9a\u6d32\u7b2c\u4e00\u4e2a\u6388\u4e88\u6c99\u82ac\u9170\u80fa\u4e0a\u5e02\u8bb8\u53ef\u7684\u56fd\u5bb6\u3002<\/p>\n
\u6b64\u6b21\u6279\u51c6\u4e3b\u8981\u57fa\u4e8e\u5728\u6d77\u5916\u56fd\u5bb6\uff08\u5305\u62ec\u97e9\u56fd\u5728\u5185\uff09\u8fdb\u884c\u7684\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167\u7684III\u671f\u7814\u7a76\uff08SETTLE\u7814\u7a76\uff09\uff0c\u4ee5\u8bc4\u4f30\u6c99\u82ac\u9170\u80fa\u4f5c\u4e3a\u6dfb\u52a0\u6cbb\u7597\u5bf9\u63a5\u53d7\u5de6\u65cb\u591a\u5df4\u6cbb\u7597\u7684\u4f34\u8fd0\u52a8\u6ce2\u52a8\u7684\u5e15\u91d1\u68ee\u75c5\u60a3\u800524\u5468\u53e3\u670d\u7ed9\u836f\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u7528\u91cf\u4e3a\u6bcf\u65e5\u4e00\u6b21\u30021<\/p>\n
\u5728SETTLE\u7814\u7a76\u4e2d\uff0c\u4e3b\u8981\u7ec8\u70b9\u662f\u81ea\u57fa\u7ebf\u81f324\u5468\u6cbb\u7597\u671f\u7684\u5e73\u5747\u6bcf\u65e5\u201c\u5f00\u201d\u671f\uff08\u6291\u5236\u5e15\u91d1\u68ee\u75c5\u75c7\u72b6\u7684\u65f6\u95f4\u6bb5\uff09\u7684\u53d8\u5316\u3002\u5173\u4e8e\u4e3b\u8981\u7ec8\u70b9\uff0c\u6c99\u82ac\u9170\u80fa\u7684\u201c\u5f00\u201d\u671f\u6bd4\u5b89\u6170\u5242\u589e\u52a0\u4e860.96\u4e2a\u5c0f\u65f6\uff0895%\u00a0CI\uff1a0.56\uff0c1.37\uff0cp<0.001\uff09\uff0c\u663e\u793a\u201c\u5f00\u201d\u671f\u663e\u8457\u5ef6\u957f\u5e76\u5177\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\u3002\u5728\u670d\u7528\u6c99\u82ac\u9170\u80fa\u7684\u60a3\u8005\u4e2d\uff0c\u6700\u5e38\u89c1\u7684\u4e09\u79cd\u836f\u7269\u4e0d\u826f\u53cd\u5e94\u4e3a\u5f02\u52a8\u75c7\u3001\u6076\u5fc3\u4e0e\u55dc\u7761\u3002<\/p>\n
\u6839\u636e\u536b\u6750\u4e0eMeiji Seika Pharma Co., Ltd.\uff08\u603b\u90e8\uff1a\u4e1c\u4eac\uff0c\u4ee5\u4e0b\u7b80\u79f0\u201cMeiji\u201d\uff09\u4e8e2017\u5e743\u6708\u7b7e\u7f72\u7684\u8bb8\u53ef\u534f\u8bae\uff0c\u536b\u6750\u83b7\u5f97\u4e86\u6c99\u82ac\u9170\u80fa\u5728\u65e5\u672c\u7684\u72ec\u5bb6\u9500\u552e\u6743\u4ee5\u53ca\u5728\u4e9a\u6d32\u7684\u5f00\u53d1\u548c\u9500\u552e\u6743\u3002Meiji\u4e8e2019\u5e749\u6708\u5728\u65e5\u672c\u83b7\u5f97\u4e86\u6c99\u82ac\u9170\u80fa\u7684\u751f\u4ea7\u548c\u9500\u552e\u8bb8\u53ef\uff0c\u536b\u6750\u4e8e2019\u5e7411\u6708\u5728\u65e5\u672c\u63a8\u51fa\u4e86\u6c99\u82ac\u9170\u80fa\u3002<\/p>\n
\u5728\u97e9\u56fd\uff0c\u7ea6\u6709150,000\u540d\u5e15\u91d1\u68ee\u75c5\u60a3\u8005\u3002\u7531\u4e8e\u76ee\u524d\u7684\u836f\u7269\u65e0\u6cd5\u5145\u5206\u63a7\u5236\u75c7\u72b6\uff0c\u6240\u4ee5\u5e15\u91d1\u68ee\u75c5\u7684\u533b\u7597\u9700\u6c42\u5c1a\u672a\u5f97\u5230\u6ee1\u8db3\uff0c\u56e0\u800c\u9700\u8981\u65b0\u7684\u6cbb\u7597\u65b9\u6848\u3002\u8fd9\u79cd\u75be\u75c5\u5728\u97e9\u56fd\u88ab\u8ba4\u5b9a\u4e3a\u7f55\u89c1\u7684\u96be\u6cbb\u6027\u75be\u75c5\u3002<\/p>\n
\u536b\u6750\u4e3a\u97e9\u56fd\u60a3\u8005\u63d0\u4f9bEquifina\u4f5c\u4e3a\u5e15\u91d1\u68ee\u75c5\u6cbb\u7597\u7684\u65b0\u9009\u62e9\uff0c\u5e76\u5c06\u8fdb\u4e00\u6b65\u6ee1\u8db3\u65e5\u672c\u548c\u4e9a\u6d32\u5e15\u91d1\u68ee\u75c5\u60a3\u8005\u53ca\u5176\u5bb6\u5c5e\u7684\u591a\u6837\u5316\u9700\u6c42\uff0c\u4e3a\u63d0\u5347\u5176\u798f\u7949\u505a\u51fa\u8d21\u732e\u3002<\/p>\n
<\/p>\n [<\/strong>\u7f16\u8005\u6ce8]<\/strong><\/p>\n 1.<\/strong>\u5173\u4e8eEqufina\uff08\u7532\u78fa\u9178\u6c99\u82ac\u9170\u80fa\uff0c\u4ee5\u4e0b\u7b80\u79f0\u201c\u6c99\u82ac\u9170\u80fa\u201d\uff09<\/strong><\/p>\n \u6c99\u82ac\u9170\u80fa\u662f\u4e00\u79cd\u9009\u62e9\u6027\u5355\u80fa\u6c27\u5316\u9176B\uff08MAO-B\uff09\u6291\u5236\u5242\uff0c\u5176\u53ef\u51cf\u5c11\u5206\u6ccc\u591a\u5df4\u80fa\u7684\u964d\u89e3\uff0c\u6709\u52a9\u4e8e\u7ef4\u6301\u5927\u8111\u4e2d\u591a\u5df4\u80fa\u7684\u6d53\u5ea6\u3002\u6b64\u5916\uff0c\u6c99\u82ac\u9170\u80fa\u53ef\u963b\u65ad\u94a0\u79bb\u5b50\u901a\u9053\u5e76\u6291\u5236\u8c37\u6c28\u9178\u91ca\u653e\uff0c\u56e0\u6b64\u5177\u6709\u4f5c\u4e3a\u4e00\u79cd\u5e15\u91d1\u68ee\u75c5\u65b0\u7597\u6cd5\u7684\u6f5c\u529b\uff0c\u8be5\u7597\u6cd5\u5177\u6709\u591a\u5df4\u80fa\u80fd\u548c\u975e\u591a\u5df4\u80fa\u80fd\u673a\u5236\u3002<\/p>\n \u6c99\u82ac\u9170\u80fa\u7531Newron Pharmaceuticals S.p.A\uff08\u603b\u90e8\uff1a\u610f\u5927\u5229\uff0c\u7c73\u5170\uff0c\u4ee5\u4e0b\u7b80\u79f0\u201cNewron\u201d\uff09\u53d1\u73b0\u548c\u5f00\u53d1\u30022011\u5e74\uff0cNewron\u4e0eMeiji\u7b7e\u8ba2\u4e86\u8bb8\u53ef\u534f\u8bae\uff0c\u6388\u4e88Meiji\u5728\u65e5\u672c\u548c\u4e9a\u6d32\u5f00\u53d1\u3001\u5236\u9020\u548c\u5546\u4e1a\u5316\u8be5\u836f\u7269\u7684\u4e13\u6709\u6743\u3002\u6839\u636e\u536b\u6750\u4e0eMeiji\u4e4b\u95f4\u7b7e\u7f72\u7684\u8bb8\u53ef\u534f\u8bae\uff0c\u536b\u6750\u62e5\u6709\u5728\u65e5\u672c\u7684\u72ec\u5bb6\u9500\u552e\u6743\u4ee5\u53ca\u5728\u4e9a\u6d32*\u7684\u5f00\u53d1\u548c\u9500\u552e\u6743\u3002\u7532\u78fa\u9178\u6c99\u82ac\u9170\u80fa\u5728\u6b27\u6d32\u3001\u7f8e\u56fd\u548c\u6fb3\u5927\u5229\u4e9a\u7b4915\u4e2a\u56fd\u5bb6\u548c\u5730\u533a\u4ee5\u201cXadago\u201d\u7684\u540d\u79f0\u9500\u552e\uff0c\u5728\u52a0\u62ff\u5927\u4ee5\u201cOnstryv\u201d\u7684\u540d\u79f0\u9500\u552e\u3002<\/p>\n * \u97e9\u56fd\u3001\u4e2d\u56fd\u53f0\u6e7e\u3001\u6587\u83b1\u3001\u67ec\u57d4\u5be8\u3001\u8001\u631d\u3001\u9a6c\u6765\u897f\u4e9a\u3001\u83f2\u5f8b\u5bbe\u3001\u5370\u5ea6\u5c3c\u897f\u4e9a\u3001\u6cf0\u56fd\u3001\u8d8a\u5357\u3001\u7f05\u7538\u3001\u65b0\u52a0\u5761\u3001\u4e2d\u56fd\u9999\u6e2f\u548c\u4e2d\u56fd\u6fb3\u95e8<\/p>\n <\/p>\n 2.<\/strong>\u5173\u4e8e\u4e34\u5e8aIII\u671f\u7814\u7a76\uff08SETTLE\u7814\u7a76\uff091<\/sup><\/strong><\/p>\n SETTLE\u7814\u7a76\u662f\u4e00\u9879\u5728\u56fd\u5916\u8fdb\u884c\u7684\u5b89\u6170\u5242\u5bf9\u7167\u3001\u53cc\u76f2\u548c\u5e73\u884c\u7ec4III\u671f\u4e34\u5e8a\u7814\u7a76\u3002\u5c06\u6bcf\u65e5\u670d\u7528\u4e00\u6b21\u7684\u6c99\u82ac\u9170\u80fa\u4f5c\u4e3a\u6dfb\u52a0\u6cbb\u7597\u5bf9\u63a5\u53d7\u5de6\u65cb\u591a\u5df4\u6cbb\u7597\u7684\u5177\u6709\u5242\u672b\u73b0\u8c61\u7684\u8fd0\u52a8\u6ce2\u52a8\u7684\u5e15\u91d1\u68ee\u75c5\u60a3\u800524\u5468\u53e3\u670d\u7ed9\u836f\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u4e0e\u5b89\u6170\u5242\u8fdb\u884c\u4e86\u6bd4\u8f83\u3002\u6c99\u82ac\u9170\u80fa\u7ec4\u4ece50mg\u5f00\u59cb\u7ed9\u836f\uff0c\u5e76\u5728\u8010\u53d7\u65f6\u589e\u52a0\u81f3100mg\u3002\u4e3b\u8981\u7ec8\u70b9\u662f\u81ea\u57fa\u7ebf\u81f324\u5468\u6cbb\u7597\u671f\u7684\u5e73\u5747\u6bcf\u65e5\u201c\u5f00\u201d\u671f\uff08\u6291\u5236\u5e15\u91d1\u68ee\u75c5\u75c7\u72b6\u7684\u65f6\u95f4\u6bb5\uff09\u7684\u53d8\u5316\uff0c\u5e76\u8bc1\u5b9e\u4e86\u6c99\u82ac\u9170\u80fa\u4f18\u4e8e\u5b89\u6170\u5242\u3002\u5173\u4e8e\u4e3b\u8981\u7ec8\u70b9\uff0c\u6c99\u82ac\u9170\u80fa\u7684\u201c\u5f00\u201d\u671f\u6bd4\u5b89\u6170\u5242\u589e\u52a0\u4e860.96\u4e2a\u5c0f\u65f6\uff0895%\u00a0CI\uff1a0.56\uff0c1.37\uff0cp <0.001\uff09\uff0c\u663e\u793a\u201c\u5f00\u201d\u671f\u663e\u8457\u5ef6\u957f\u5e76\u5177\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\u3002\u5728\u8fd9\u9879\u7814\u7a76\u4e2d\uff0c\u5b89\u6170\u5242\u7684\u836f\u7269\u4e0d\u826f\u53cd\u5e94\uff08ADR\uff09\u53d1\u751f\u7387\u4e3a27.6%\uff0c\u6c99\u82ac\u9170\u80fa\u7684\u836f\u7269\u4e0d\u826f\u53cd\u5e94\u53d1\u751f\u7387\u4e3a28.5%\u3002\u5728\u670d\u7528\u6c99\u82ac\u9170\u80fa\u7684\u60a3\u8005\u4e2d\uff0c\u6700\u5e38\u89c1\u7684\u4e09\u79cd\u836f\u7269\u4e0d\u826f\u53cd\u5e94\u4e3a\u5f02\u52a8\u75c7\u3001\u6076\u5fc3\u4e0e\u55dc\u7761\u3002<\/p>\n <\/p>\n 3.<\/strong>\u5173\u4e8e\u5e15\u91d1\u68ee\u75c5<\/strong><\/p>\n \u5e15\u91d1\u68ee\u75c5\u662f\u4e00\u79cd\u5f15\u8d77\u8fd0\u52a8\u969c\u788d\u7684\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\uff0c\u75c7\u72b6\u5305\u62ec\u80a2\u4f53\u9707\u98a4\u3001\u808c\u5f3a\u76f4\u548c\u6b65\u6001\u969c\u788d\u3002\u8fd9\u662f\u7531\u591a\u5df4\u80fa\u795e\u7ecf\u7cfb\u7edf\u9000\u5316\u5bfc\u81f4\u591a\u5df4\u80fa\u4e0d\u8db3\u800c\u5f15\u8d77\u7684\uff0c\u591a\u5df4\u80fa\u662f\u5927\u8111\u4e2d\u7684\u4e00\u79cd\u795e\u7ecf\u9012\u8d28\u3002\u636e\u4f30\u8ba1\uff0c\u97e9\u56fd\u7ea6\u6709150,000\u540d\u5e15\u91d1\u68ee\u75c5\u60a3\u8005\uff08\u536b\u6750\u5185\u90e8\u4f30\u8ba1\uff09\u3002\u4e9a\u6d32\u7ea6\u6709300\u4e07\u540d\u5e15\u91d1\u68ee\u75c5\u60a3\u8005\uff0c2<\/sup>\u65e5\u672c\u7ea6\u6709200,000\u540d\u5e15\u91d1\u68ee\u75c5\u60a3\u8005\uff0c3<\/sup>\u968f\u7740\u4eba\u53e3\u8001\u9f84\u5316\uff0c\u60a3\u8005\u6570\u91cf\u6b63\u9010\u6b65\u589e\u52a0\u30024<\/sup>\u5de6\u65cb\u591a\u5df4\u901a\u8fc7\u8865\u5145\u8111\u5185\u591a\u5df4\u80fa\u800c\u5e7f\u6cdb\u7528\u4e8e\u6cbb\u7597\u5e15\u91d1\u68ee\u75c5\u3002\u7136\u800c\uff0c\u968f\u7740\u75be\u75c5\u8fdb\u5c55\uff0c\u5de6\u65cb\u591a\u5df4\u7684\u7597\u6548\u6301\u7eed\u65f6\u95f4\u4f1a\u51cf\u5c11\uff0c\u5728\u67d0\u4e9b\u60c5\u51b5\u4e0b\uff0c\u60a3\u8005\u53ef\u80fd\u4f1a\u51fa\u73b0\u5242\u672b\u73b0\u8c61\uff0c\u5373\u5728\u4e0b\u4e00\u6b21\u7ed9\u836f\u4e4b\u524d\u5e15\u91d1\u68ee\u75c5\u75c7\u72b6\u518d\u6b21\u51fa\u73b0\u3002\u4e3a\u9632\u6b62\u5242\u672b\u73b0\u8c61\uff0c\u56e0\u800c\u91c7\u7528\u4e0e\u5de6\u65cb\u591a\u5df4\u5177\u6709\u4e0d\u540c\u4f5c\u7528\u673a\u5236\u7684\u836f\u7269\u8054\u5408\u6cbb\u7597\u3002<\/p>\n <\/p>\n 1<\/sup>\u00a0Schapira AH et al. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.\u00a0JAMA Neurol.<\/em>\u00a02017;74(2):216-224 \u536b\u6750\u682a\u5f0f\u4f1a\u793e\uff08\u603b\u90e8\uff1a\u4e1c\u4eac\uff0c\u9996\u5e2d\u6267\u884c\u5b98\uff1a\u5185\u85e4\u6674\u592b\uff0c\u4ee5\u4e0b\u7b80\u79f0\u201c\u536b\u6750\u201d\uff09\u8fd1\u65e5\u5ba3\u5e03\uff0c\u536b\u6750\u5728\u97e9\u5b50\u516c\u53f8\u536b\u6750\u682a\u5f0f\uff08\u97e9\u56fd\uff09\u4f1a\u793e\u5df2\u83b7\u5f97\u97e9\u56fd\u76d1\u7ba1\u673a\u6784\uff08\u98df\u54c1\u548c\u836f\u54c1\u5b89\u5168\u90e8\uff09\u6240\u6388\u4e88\u7684\u5173\u4e8e\u5e15\u91d1\u68ee\u75c5\u6cbb\u7597\u836f\u7269Equfina\u00ae\uff08\u7532\u78fa\u9178\u6c99\u82ac\u9170\u80fa\uff0c\u4ee5\u4e0b\u7b80\u79f0\u201c\u6c99\u82ac\u9170\u80fa\u201d\uff09\u7684\u4e0a\u5e02\u8bb8\u53ef\uff0c\u8be5\u836f\u4f5c\u4e3a\u542b\u5de6\u65cb\u591a\u5df4\u836f\u7269\u7684\u52a0\u7528\u6cbb\u7597\uff0c\u7528\u4e8e\u6cbb\u7597\u4f34\u5242\u672b\u8fd0\u52a8\u6ce2\u52a8\u7684\u539f\u53d1\u6027\u5e15\u91d1\u68ee\u75c5\u60a3\u8005\u30022019\u5e747\u6708\u5df2\u4e8e\u97e9\u56fd\u63d0\u4ea4\u6c99\u82ac\u9170\u80fa\u7684\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\uff0c\u901a\u8fc7\u6279\u51c6\u8be5\u7533\u8bf7\uff0c\u97e9\u56fd\u6210\u4e3a\u9664\u65e5\u672c\u4e4b\u5916\u4e9a\u6d32\u7b2c\u4e00\u4e2a\u6388\u4e88\u6c99\u82ac\u9170\u80fa\u4e0a\u5e02\u8bb8\u53ef\u7684\u56fd\u5bb6\u3002<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-2732","post","type-post","status-publish","format-standard","hentry","category-news-zh"],"_links":{"self":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2732"}],"collection":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/comments?post=2732"}],"version-history":[{"count":3,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2732\/revisions"}],"predecessor-version":[{"id":5964,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2732\/revisions\/5964"}],"wp:attachment":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/media?parent=2732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/categories?post=2732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/tags?post=2732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n\u5a92\u4f53\u54a8\u8be2\uff1a<\/strong>
\n\u536b\u6750\u682a\u5f0f\u4f1a\u793e
\n\u516c\u5171\u5173\u7cfb\u90e8
\n+81-(0)3-3817-5120<\/p>\n
\n2<\/sup>\u00a0E Ray Dorsey et al. Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016\u00a0Lancet Neurol.<\/em>2018;17:939-53
\n3<\/sup>\u00a0Japanese Society of Neurology. Treatment and Management Guideline 2018 for Parkinson\u2019s Disease
\n4<\/sup>\u00a0Japan Intractable Diseases Information Center: http:\/\/www.nanbyou.or.jp\/<\/p>\n","protected":false},"excerpt":{"rendered":"